FAPI-PET shows promise in head and neck cancer patients

In this study, the researchers tested the approach for the first time in head and neck cancer patients with tumors of unknown origin in a prospective clinical trial.PET/CT and MR images of a 72-year-old woman. (A) F-18 FDG-PET images (left and top) and PET/CT images (bottom) shown in coronal, sagittal, and axial views (from left to right), demonstrated a metastatic lymph node of the right neck with intensive metabolic activity (black arrow, SUVmax, 30.1) but presented no evidence for primary tumor. (B) Ga-68 FAPI-PET images (top and right) and PET/CT images (bottom), shown in axial, sagittal, and coronal views (from left to right), also detected metastatic lymph node with high Ga-68 FAPI tracer activity (black arrow, SUVmax, 16.3). There was intensive uptake of Ga-68 FAPI in palate (red arrow, SUVmax, 11.3). (C) T1-weighted, T2-weighted, and contrast-enhanced T1-weighted MRI also presented no evidence for primary tumor. Subsequent surgery confirmed mucoepidermoid carcinoma of palate. Image courtesy of the Journal of Nuclear Medicine. The group enrolled 91 patients (18 women, 73 men; median age, 60 years old) with negative or equivocal findings of primary tumors by a comprehensive clinical examination and conventional imaging. Between June 2020 and September 2022, they performed F-18 FDG and (Ga-68) FAPI-PET/CT within one week, with the presence of primary tumors on the imaging sets then recorded by three experienced nuclear medicine physicians. Primary tumors were detecte...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Molecular Imaging Radiation Oncology/Therapy Source Type: news